1. Home
  2. PCRX vs AVXL Comparison

PCRX vs AVXL Comparison

Compare PCRX & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$20.82

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.91

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
AVXL
Founded
2006
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
397.6M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
AVXL
Price
$20.82
$4.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$35.33
$22.00
AVG Volume (30 Days)
995.1K
2.1M
Earning Date
02-26-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$716,791,000.00
N/A
Revenue This Year
$6.21
N/A
Revenue Next Year
$8.26
N/A
P/E Ratio
$43.81
N/A
Revenue Growth
3.14
N/A
52 Week Low
$19.84
$2.86
52 Week High
$27.64
$13.99

Technical Indicators

Market Signals
Indicator
PCRX
AVXL
Relative Strength Index (RSI) 29.89 66.01
Support Level $22.52 $4.11
Resistance Level $26.48 $4.44
Average True Range (ATR) 1.21 0.27
MACD -0.61 0.18
Stochastic Oscillator 2.69 96.25

Price Performance

Historical Comparison
PCRX
AVXL

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: